(Q36756632)

16 August 2017

0 references

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials (English)

1 reference

16 August 2017

1 reference

1 reference

3

Niccolò Marchionni

1 reference

16 August 2017

1

Matteo Monami

1 reference

16 August 2017

4

Edoardo Mannucci

1 reference

16 August 2017

Caterina Lamanna

2

1 reference

PMC publication ID

2453648

16 August 2017

language of work or name

English

0 references

publication date

28 March 2008

1 reference

16 August 2017

1 reference

16 August 2017

31

1 reference

16 August 2017

7

1 reference

16 August 2017

1455-1460

1 reference

Polycystic ovary syndrome and endometrial cancer

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Metformin and glitazones: do they really help PCOS patients?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Metformin and reduced risk of cancer in diabetic patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

A phase II trial with rosiglitazone in liposarcoma patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Rosiglitazone and cardiovascular risk.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453648

Rosiglitazone and cardiovascular risk

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18375416

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18375416

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DC07-2308

1 reference

16 August 2017

1 reference

PMC publication ID

2453648

16 August 2017

PubMed publication ID

18375416

1 reference

PMC publication ID

2453648